Moreover, dysregulation of lipid metabolism contributes to MASLD progression by inducing hepatocyte death and has been actively investigated as a therapeutic target for MASLD (84), but its role in sAH and whether it can be used as a therapeutic target for ALD is unclear. This evidence concerns the gene ACSM3 and metabolic dysfunction-associated steatotic liver disease.